Q-omics provides the consensus-scored TUBB4B profile across patient tissues and cancer cell-line models. TUBB4B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, TUBB4B is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, TUBB4B protein abundance shows 22,906 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UCS, LIHC, and PDAC as cancer lineages where TUBB4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBB4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBB4B survival associations across molecular data types. TUBB4B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBB4B RNA expression–survival associations across cancer types. High TUBB4B expression shows unfavorable associations in UCS, ACC, LGG, MESO and LIHC, but favorable associations in UCEC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for TUBB4B RNA expression.
This table summarizes TUBB4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TUBB4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBB4B shows higher tumor expression in LIHC, STAD, HNSC, BRCA, LUSC and CHOL. The LIHC box plot shows higher TUBB4B RNA expression in tumor versus normal tissue (log2 FC = +0.944, t-test p < 0.001).
This table shows molecular features associated with TUBB4B in patient tissues and cancer cell lines. In patient samples, TUBB4B shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TUBB4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
